To test our hypothesis, we measured the plasma AACS signatures from N = 33 hormone receptor positive, HER2 negative advanced breast cancer patients who were recommended for but had not yet started CDKi treatment, meaning that they were baseline naïve for CDKi’s. Here, NR4A1 is linked to breast carcinoma.